蒙药抗绝经后骨质疏松的研究进展  

Research Progress of Mongolian Medicine against Postmenopausal Osteoporosis

作　　者：包玉龙 佟雁翔[2] 

机构地区：[1]内蒙古医科大学研究生学院,内蒙古 呼和浩特 [2]内蒙古医科大学第二附属医院创伤外科中心A区,内蒙古 呼和浩特

出　　处：《临床医学进展》2024年第10期1086-1092,共7页Advances in Clinical Medicine

摘　　要：骨质疏松症(osteoporosis, OP)是最为常见的十种疾病之一,随着我国人口老龄化,骨质疏松患者逐年增加,尤其是绝经后女性远大于男性。绝经后骨质疏松症(postmenopausal osteoporosis, PMOP)在OP中发病率最高的一种,其发生与雌激素分泌降低,体力活动减少,营养不平衡或相对不足,以及随年龄增加,机体衰老、损伤和修复的变化,以及骨细胞和组织增殖、分化、功能减退等内在因素的综合作用所致,除此之外氧化应激、肠道菌群和铁过载都会影响PMOP的发病。蒙医称OP为“骨枯症”,本研究从蒙医对骨质疏松的药物疗法进行分析研究和展望。Osteoporosis (OP) is one of the ten most common diseases. With the aging of the population, the number of osteoporosis patients has increased year by year, especially postmenopausal women are much more than men. Postmenopausal osteoporosis (PMOP) is one of the most common forms of OP. Its occurrence is associated with decreased estrogen secretion, reduced physical activity, nutritional imbalance or relative insufficiency, and changes in aging, injury and repair as the body ages, as well as intrinsic factors such as bone cell and tissue proliferation, differentiation and dysfunction. In addition, oxidative stress, intestinal flora and iron overload affect the pathogenesis of PMOP. OP is called “bone blight disease” in Mongolian medicine. This study analyzed and studied the drug therapy of osteoporosis from Mongolian medicine.

关 键 词：蒙药 骨质疏松 绝经后骨质疏松 

分 类 号：R58[医药卫生—内分泌]